Akums Drugs hosts investor meet on Sep 22 at Taj Mumbai

0 min read | Published on 16 Sept 2026, 04:30 PM |Updated on 16 Sept 2026, 04:54 PM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

Akums Drugs & Pharma to host investor meet on September 22, 2026
Session part of G200 Summit 2026 at Taj Santacruz, Mumbai
Meeting starts at 10:00 am and will be conducted in person

*this image is generated using AI for illustrative purposes only.

Akums Drugs & Pharmaceuticals Limited will participate in an investor and analysts meet on September 22, 2026, as part of the G200 Summit 2026. The event is scheduled to begin at 10:00 am at the Taj Santacruz in Mumbai.

The company disclosed the schedule pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meet is classified as a group session and will be conducted in person.

Meeting Details

The interaction aims to provide investors and analysts with updates on the company’s business operations. Akums confirmed that no unpublished price-sensitive information will be shared during the session. The schedule remains subject to change based on exigencies from either the company or the participants.

Event	Date	Time	Location	Mode
G200 Summit 2026	September 22, 2026	10:00 am	Taj, Santacruz, Mumbai	Physical

The disclosure was signed by Dharamvir Malik, Company Secretary and Compliance Officer, and uploaded to the company website.

Historical Stock Returns for Akums Drugs & Pharma

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.83%	+4.81%	+6.25%	+64.15%	+64.13%	-3.05%

How might Akums Drugs' strategic updates at the G200 Summit influence its stock valuation and analyst target prices in the immediate aftermath?

Will the company announce any new pipeline developments or R&D milestones during the session that could impact its long-term growth trajectory?

How does Akums Drugs plan to address current competitive pressures in the pharmaceutical sector based on the operational updates expected at this meet?

Akums Drugs & Pharma

View Company Insights

View All News

Akums Drugs receives ESG rating of 65 for FY26 from NSE Sustainability

0 min read | Published on 03 Sept 2026, 04:31 PM |Updated on 03 Sept 2026, 04:31 PM

Reviewed by

Naman SScanX News Team

Add as a preferred
source on Google

Key Highlights

Akums Drugs received an ESG rating of 65 for FY26
NSE Sustainability assigned the score voluntarily
Assessment based on publicly available information
Disclosure made under SEBI Regulation 30

*this image is generated using AI for illustrative purposes only.

Akums Drugs & Pharma received an environmental, social, and governance (ESG) rating of 65 for FY26 from NSE Sustainability Ratings & Analytics Limited on September 2, 2026.

The company disclosed the development in a filing with the National Stock Exchange of India Ltd. and BSE Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure aligns with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated July 11, 2023, which was updated on January 30, 2026.

Rating Methodology

NSE Sustainability, a subsidiary of NSE Indices Limited and a registered ESG Rating Provider, assigned the score voluntarily. Akums Drugs confirmed it did not engage the agency for this assessment. The rating was derived solely from publicly available information.

The filing notes that the rating link is available via the NSE ESG Rating platform. Dharamvir Malik, Company Secretary & Compliance Officer, signed the intimation on September 3, 2026.

Historical Stock Returns for Akums Drugs & Pharma

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.83%	+4.81%	+6.25%	+64.15%	+64.13%	-3.05%

How might Akums Drugs' ESG rating of 65 influence its access to green financing or sustainable investment funds in the coming fiscal year?

What specific operational changes or sustainability initiatives is Akums Drugs likely to prioritize to improve its ESG score in future assessments?

How does this voluntary ESG rating position Akums Drugs relative to its key competitors in the Indian pharmaceutical sector regarding regulatory compliance and investor appeal?

Akums Drugs & Pharma

View Company Insights

View All News